MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Leucine-rich repeat kinase 2(LRRK2)"

  • 2018 International Congress

    Validation of protein phosphatases that regulate the LRRK2 phosphorylation cycle

    M. Drouyer, M. Emanuele, R. Lefebvre, K. Cailliau-Maggio, A. martoriati, T. Comptdaer, P. Semaille, E. Mutez, W. Sibran, N. Wolkoff, E. Lobbestael, M. Bolliger, V. Baekelandt, J. Nichols, MC. Chartier-Harlin, JM. Taymans (Lille, France)

    Objective: To identify and validate candidate phosphatases regulating the LRRK2 phosphorylation cycle. Background: Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are one…
  • 2018 International Congress

    Comparison of thermal sensation and pain thresholds in LRRK2 carriers and non carriers with Parkinson’s disease

    A. Khlebtovsky, Y. Roditi, R. Djaldetti (Petach Tikva, Israel)

    Objective: To compare between clinical findings and quantitative sensory testing (QST) data in patients with Parkinson's disease (PD) positive and negative for mutations in LRKK2.…
  • 2018 International Congress

    Molecular Genetics and Functional Studies of LRRK2 Gene Variations in Parkinson’s Disease

    M-L. Chen, R-M. Wu (Taipei, Taiwan)

    Objective: To evaluate the function role of ROC domain in the brains of LRRK2 transgenic mice model and normal control mice. Background: Mutations in leucine-rich…
  • 2018 International Congress

    PD associated with GBA and LRRK2 mutations: Genotype-phenotype correlation

    V. Livneh, G. Yahalom, L. Greenbaum, S. Israeli-Korn, T. Fay-Karmon, S. Hassin, Z. Gan Or (Ramat Gan, Israel)

    Objective: To study differences in disease characteristics in PD associated with 1 or 2 mutations in the most common PD-associated genes in the Ashkenazi Jewish…
  • 2018 International Congress

    Activation of chaperone-mediated autophagy reduces oligomeric alpha-synuclein accumulation in LRRK2(R1441G) knockin mouse model of Parkinson’s disease (PD)

    P.W.L. Ho, C.S.C. Lam, M.C.T. Leung, S.Y.Y. Pang, H.F. Liu, L. Li, M.H.W. Kung, D. Ramsden, SL. Ho (Hong Kong)

    Objective: To determine age-dependent accumulation of oligomeric alpha-synuclein in the brain of aged LRRK2(R1441G) knockin mice; and to explore whether activation of chaperone-mediated autophagy (CMA)…
  • 2018 International Congress

    Application of the Movement Disorder Society Prodromal Criteria in healthy G2019S-LRRK2 carriers

    A. Mirelman, R. Saunders-Pullman, R. Alcalay, S. Shustak, A. Thaler, B. Cohen, A. Hillel, T. Gurevich, D. Raymond, H. Mejia-Santana, L. Ozelius, L. Clark, M. Gana-Weisz, A. Bar-Shira, A. Orr-Urtreger, S. Bressman, K. Marder, N. Giladi (Tel Aviv, Israel)

    Objective: To evaluate the MDS prodromal criteria in first-degree relatives of Ashkenazi Jewish G2019S-LRRK2 PD patients, who are considered a population at risk for developing…
  • 2018 International Congress

    Survival of patients with Parkinson’s disease is influenced by the mutations in the LRRK2 but not GBA gene

    A. Thaler, T. Kozlovski, T. Gurevich, A. Bar Shira, M. Gana-Weisz, A. Orr-Urtreger, L. Goldstein, N. Giladi, A. Mirelman (Tel-Aviv, Israel)

    Objective: To assess the impact of common genetic mutations on Parkinson's disease survival. Background: The prognosis of Parkinson's disease (PD) is heterogeneous with many factors…
  • 2018 International Congress

    Resting state networks abnormalities among healthy LRRK2 mutation carriers

    A. Thaler, Y. Jacob, T. Gurevich, R. Helmich, B. Bloem, A. Orr-Urtreger, N. Giladi, L. Yahimovich, A. Mirelman, T. Hendler (Tel-Aviv, Israel)

    Objective: To assess the integrity of resting state networks in non-manifesting carriers of the G2019S mutation in the LRRK2 gene. Background: Non-manifesting first degree relatives…
  • 2018 International Congress

    A review of modifiers of Parkinsonism in the Leucine-rich repeat kinase 2 (LRRK2) population

    J. Staisch (Portland, OR, USA)

    Objective: To review and examine the most current identified modifiers of Parkinsonism in the LRRK2 population. Background: LRRK2 is a protein with multiple domains and…
  • 2018 International Congress

    Full sequencing and haplotype analysis reveals LRRK2 protective haplotype in REM sleep behavior disorder

    B. Ouled Amar-Bencheikh, J. Ruskey, I. Arnulf, Y. Dauvilliers, C. Charley Monaca, V. Cochen De-Cock, JF. Gagnon, D. Spiegelman, M. Hu, B. Högl, A. Stefani, L. Ferini-Strambi, G. Plazzi, E. Antelmi, P. Young, A. Heidbreder, B. Mollenhauer, F. Sixel-Döring, C. Trenkwalder, W. Oertel, J. Montplaisir, R. Postuma, G. Rouleau, Z. Gan-Or (Montreal, QC, Canada)

    Objective: To examine the role of LRRK2 mutations and variants in susceptibility for RBD. Background: Rapid eye movement (REM)-sleep behavior disorder (RBD) is, in most…
  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 19
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley